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ORIGINAL PAPER
In uence of two different inhalation devices on
therapy compliance in asthmatic patients
Constant Paul van Schayck1,2, Ingrid Desire´e Bijl-Hoand1, Hans Folgering3, Sonja Gerarda
Martina Cloosterman1, Reinier Akkermans1, Frank v.d. Elshout4 and Chris van Weel1
1Department of General Practice and Social Medicine, University of Nijmegen, 2Department of General Practice,
University of Maastricht, 3Department of Pulmonary Diseases, Dekkerswald, University of Nijmegen, 4Department of
Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands.
daily frequency were 90.8% (25–75th percentile 61.6–98.0%) andScand J Prim Health Care 2002;20:126–128. ISSN 0281-3432
78.5% (25–75th percentile 49.0%-91.2%), respectively (pB0.001).
Objective – To examine the in uence of inhalation device (Autohaler The duration of treatment period had a signi cant negative in uence
on compliance when four times daily dosage frequency was prescribedversus metered dose inhaler) and patients’ subjective opinion towards
(p 5 0.05).the different devices, as well as daily frequency and duration of
Conclusion – In conclusion, the devices (metered dose inhaler andtreatment on medication compliance.
Design – Prospective study measuring compliance in the same pa- Autohaler) and the patients’ opinion about the devices did not
signi cantly contribute to the compliance rates. Compliance towardstients of the Autohaler twice daily with the metered dose inhaler
the medication treatment, however, is negatively in uenced by a hightwice daily, as well the Autohaler twice daily with the Autohaler four
times daily. daily frequency.
Setting – Primary health care.
Subjects – 34 subjects with asthma. Key words: asthma, compliance, inhalation device.
Main outcome measures – Patients preference and compliance.
Results – Patients preferred the Autohaler. The percentage of pa-
Chris van Weel, Department of General Practice and Socialtients with a negative opinion towards the metered dose inhaler was
38% compared with 12% towards the Autohaler. The median values Medicine, University of Nijmegen, P.O. Box 9101, 6500 HB Nijme-
gen, The Netherlands. E-mail: T.Jeijsman@hsv.kun.nlof the compliance rate of the Autohaler with twice and four times
Non-compliance occurs particularly in patients with
chronic illness and with variable symptoms over time,
as in asthma. Non-compliance in asthma might con-
tribute to its morbidity (1). In order to prevent poor
compliance and prescribe effectively, physicians
should take into account treatment factors that con-
tribute to poor compliance.
The breath-actuated inhaler (Autohaler) is a device
that is triggered by the inspiratory air ow produced
by the patient. It is easier to use than the metered
dose inhaler (MDI), because patients are not depen-
dent on hand–lung coordination, which could in u-
ence compliance. We therefore studied the effect of
the inhalation device (Autohaler and MDI) on medi-
cation compliance in asthmatic patients and deter-
mined the in uence on compliance of patients’
subjective opinion about both devices.
Patients with chronic air ow obstruction often use
different drugs in combination with regimen requir-
ing multiple daily dosage during a long period. It is
known that a prescribed frequent daily use results in
poor compliance (2,3). We investigated the compli-
ance rates with different daily frequency by means of
an Autohaler, which we expected to show a more
positive effect on compliance compared with the
MDI. We also investigated the effect of duration of
treatment on the degree of compliance.
MATERIAL AND METHODS
Patients
Asthmatic patients were recruited from a research
project investigating the effect of bronchodilator
treatment on air ow sensitivity in a placebo-con-
trolled design (4). Patients used three inhalers daily,
two Autohalers and one MDI, over a period of 12
weeks. One Autohaler had to be used twice daily, the
other four times daily. The MDI had to be used twice
daily. Extensive instruction on how to use the differ-
ent devices was given by a lung function technician
before the start of the trial. The trial was approved
by the Ethics Committee of the University of Nijme-
gen and informed consent was obtained from each
patient.
Assessment of medication compliance
Medication was weighed before and after use in order
to assess the amount used. Devices were collected
without prior announcement (5) and new ones deliv-
ered 6 weeks after the start of the trial during a
regular visit to the homes of patients. Furthermore,
medication was collected when the patient visited the
laboratory at the end of the study period. Medication
compliance rates were expressed as: medication used
as a percentage of medication prescribed.
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Patients’ opinions towards the inhalation device
After 6 weeks, we sought the subjective opinions of
patients about the different devices by asking the
following question: ‘‘What do you think about use of
the device?’’ This question was asked for each different
type of device. Patients’ subjective opinions were
divided into three groups: inconvenient, neutral and
convenient.
Analysis
Differences were analysed by Wilcoxon test if the
compliance rates were not normally distributed. Values
are expressed as medians with 25–75th percentile
ranges.
Power
A clinically relevant difference of 12.5% in medication
compliance (1,5) can be detected with an a of 0.05 and
a b of 0.20 and a standard deviation of 25% with a
sample size of at least 34 subjects.
RESULTS
Patients
The total number of patients meeting the inclusion
criteria was 34, which was suf cient for the power
needed. Their mean age was 37 (SD 13) years, 19 were
women, PC20 (geometric mean) was 0.92 mg histamine:
ml (95% CI 0.48–1.75), FEV1% of predicted was 80%
(SD 18).
Medication compliance
The median value of the compliance rate of the total
amount of medication used, expressed as a percentage
of the prescribed medication, was 87.1% (25–75th
percentile 61.8%–94.6%). In 65% of the patients,
compliance rates were between 80% and 120%. Under-
use (less than 80% of the prescribed dose) was far more
common than overuse (above 120% of the prescribed
dose), in 34% and 1.0% of the patients, respectively.
Effect of device, daily frequency and treatment
period
There was no effect of device on medication compli-
ance (p¾0.317). The median values for the compliance
rate of the MDI and the Autohaler (with twice daily
frequency) were 95.7% (25–75th percentile 83.9–
99.9%) and 90.8% (25–75th percentile 61.6–98.0%),
respectively. The median values for the compliance rate
of the Autohaler with twice and four times daily
frequency were 90.8% (25–75th percentile 61.6–
98.0%) and 78.5% (25–75th percentile 49.0–91.2%),
respectively, and differed signi cantly (p¾0.001).
There was a signi cant effect of treatment period on
medication compliance in the Autohaler that had to be
used four times daily (p¾0.05). The median compli-
ance percentage of the Autohaler (four times daily) was
79.6% (25–75th percentile 54.8–90.8%) in the  rst 6
weeks of the trial and 75.6% (25–75th percentile
48.4–90.7%) in the second half of the study period.
Patients’ opinions towards the MDI and the
autohaler
The numbers of patients who evaluated their device as
inconvenient, neutral and convenient are presented in
Fig. 1. The mean compliance percentage in patients
with a negative opinion towards the MDI and the
Autohaler was 83% (SD¾30%) and 61% (SD¾39%),
respectively. In patients with a positive opinion to-
wards the MDI and the Autohaler, compliance rates
were 77% (SD¾38%) and 74% (SD¾35%), respec-
tively.
DISCUSSION
The results of the present study show that there was
no difference in compliance between the two different
inhalation devices (MDI and Autohaler). This con-
trasts with our expectation that patients would be more
compliant with use of the Autohaler than with use of
the MDI. A possible explanation could be that the
Autohaler is a relatively new device compared with the
MDI, and some patients might be relatively unfamiliar
with it. There were more patients who disliked theMDI
than there were patients who found the Autohaler
inconvenient. Opinions about the devices, however, did
not seem to have an in uence on medication compli-
ance. A corresponding conclusion has been found by
Arshad et al. (6), who reported that no signi cant
Fig. 1. Patients’ subjective opinions concerning the
inhalation device (n¾34, MDI¾metered dose in-
haler) ( ¾ inconvenient; ¾neutral; ¾conve-
nient).
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difference was identi ed between the Autohaler and
the MDI in respect of bronchodilator usage.
In this study, we observed that the most important
factor for compliance was the relatively highly pre-
scribed frequency of four times daily. It has been
reported earlier that compliance is reduced when daily
dosage is doubled (2). Therefore, when the impact of
compliance is included in determining medication
treatment, a low daily frequency is obviously prefer-
able to a high daily frequency. This is relevant for
medical care when we compare, for instance, short-act-
ing with long-acting bronchodilators. In conclusion,
the devices (MDI and Autohaler) and patients’ opin-
ions about the devices did not signi cantly contribute
to the compliance rates. Compliance towards medica-
tion treatment, however, is negatively in uenced by
high daily frequency.
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